For more information regarding these studies, contact Cancer Research and Registry at (601) 984-1095.
A071102: Testing Temozolomide with Veliparib Or Placebo In Specific Patients with Newly Diagnosed Glioblastoma Multiforme
This study is for patients who have a type of brain tumor called a glioblastoma multiforme (GBM) and that have completed the first part of treatment with radiation combined with the chemotherapy drug temozolomide (TMZ).
The purpose of this study is to compare the effects, good or bad, of the usual treatment (temozolomide) with or without the addition of the investigational drug veliparib for people whose brain tumors show a change in a small region of DNA (gene) called O6-methylguanine methyltransferase (MGMT). The use of TMZ is the standard of care. The combination of veliparib with TMZ is experimental. Veliparib is an investigational drug that has not been approved by the FDA for any indication.Principal Investigator: Mark Anderson, MD
A071401: Phase II Trial Of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations
METIS EF-25: Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC).
Campus Maps / Parking
2500 North State Street
Jackson, MS 39216
General Information: 601-984-1000
Patient Appointments: 888-815-2005